Results 31 to 40 of about 4,153 (212)

Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes [PDF]

, 2023
Background: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes.
Agarwal, Rajiv, Anker, Stefan D., Bakris, George L., Cruzado, Josep Ma., FIDELIO-DKD Investigators, Filippatos, Gerasimos S., Joseph, Amer, Kolkhof, Peter, Nowack, Christina, Pitt, Bertram, Rossing, Peter, Ruilope, L. M., Schloemer, Patrick   +12 more
core   +1 more source

Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis

Kidney Medicine, 2023
Rationale & Objective: In FIDELITY, finerenone improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes. This analysis explores the efficacy and safety of finerenone in Hispanic patients.
Sylvia E. Rosas, Luis M. Ruilope, Stefan D. Anker, Bertram Pitt, Peter Rossing, Andres Angelo Cadena Bonfanti, Ricardo Correa-Rotter, Fernando González, Carlos Francisco Jaramillo Munoz, Pablo Pergola, Guillermo E. Umpierrez, Andrea Scalise, Charlie Scott, Robert Lawatscheck, Amer Joseph, George L. Bakris   +15 more
doaj   +1 more source

New Insights in the Diagnosis and Treatment of Heart Failure [PDF]

, 2015
Cardiovascular disease is the leading cause of mortality in the US and in westernized countries with ischemic heart disease accounting for the majority of these deaths.
Agnetti, G, Nicolini, F, Piepoli, MF, Siniscalchi, G   +3 more
core   +5 more sources

Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus

Diabetology & Metabolic Syndrome, 2023
Background Finerenone is a third-generation mineralocorticoid receptor antagonists, which has shown good cardiac function improvement in patients with type 2 diabetes in large-scale clinical trials.
Tao Jin, Xiangrui Fu, Ming Liu, Fengshuang An   +3 more
doaj   +1 more source

Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease

Cardiovascular Diabetology, 2022
Objective To evaluate the cardiovascular and renal benefits of finerenone, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients with Type 2 Diabetes Mellitus (T2DM) and chronic kidney ...
Yaofu Zhang, Li Jiang, Junheng Wang, Tongxin Wang, Chieh Chien, Weijun Huang, Xiaozhe Fu, Yonghua Xiao, Qiang Fu, Shidong Wang, Jinxi Zhao   +10 more
doaj   +1 more source

The urinary albumin-to-creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease. [PDF]

J Intern Med
Abstract Increased urinary albumin excretion is a strong predictor for cardiovascular events in persons with and without decreased glomerular filtration rate and can be assessed with the urinary albumin‐to‐creatinine ratio (UACR), which is a selective, sensitive, and convenient method for patients.
Kramer HJ, Bakris GL.
europepmc   +2 more sources

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: A systematic review and meta-analysis [PDF]

, 2016
Background: Hypertension and proteinuria are critically involved in the progression of chronic kidney disease. Despite treatment with renin angiotensin system inhibition, kidney function declines in many patients.
Boesby, L. (Lene), Currie, G. (Gemma), Delles, C. (Christian), Edwards, N.C. (Nicola C.), Ferro, C.J. (Charles J.), Fujita, T. (Toshiro), Jardine, A.G. (Alan G.), Lindhardt, M. (Morten), Mark, P.B. (Patrick B.), Meiracker, A.H. (Anton) van den, Ohtsu, H. (Hiroshi), Oveisi, S. (Sonia), Preiss, D.J. (David J.), Rossing, K., Saklayen, M.G. (Mohammad G.), Taylor, A.H.M. (Alison H. M.), Townend, J. (Jonathan)   +16 more
core   +1 more source

Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis:A FIDELITY subgroup analysis [PDF]

, 2023
AimInvestigating the effect of finerenone on liver function, cardiovascular and kidney composite outcomes in patients with chronic kidney disease and type 2 diabetes, stratified by their risk of liver steatosis, inflammation and fibrosis.
Anker, Stefan D., Bakris, George L., Birkenfeld, Andreas L., Bornstein, Stefan R., Demir, Münevver, Filippatos, Gerasimos, Kolkhof, Peter, Lawatscheck, Robert, Linkermann, Andreas, Perakakis, Nikolaos, Pitt, Bertram, Rossing, Peter, Ruilope, Luis M., Scott, Charlie   +13 more
core   +1 more source

Deleting death and dialysis: Conservative care of cardio-vascular risk and kidney function loss in chronic kidney disease (CKD) [PDF]

, 2018
The uremic syndrome, which is the clinical expression of chronic kidney disease (CKD), is a complex amalgam of accelerated aging and organ dysfunctions, whereby cardio-vascular disease plays a capital role. In this narrative review, we offer a summary of
Castillo-Rodriguez, Esmeralda, Glorieux, Griet, Ortiz, Alberto, Van Laecke, Steven, Vanholder, Raymond, Verbeke, Francis   +5 more
core   +4 more sources

Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis

Indian Journal of Endocrinology and Metabolism, 2022
Background: Data are scant on use of finerenone in diabetic kidney disease (DKD). We undertook this meta-analysis to address this knowledge gap. Methods: Electronic databases were searched for randomized controlled trials (RCTs) involving diabetes ...
Deep Dutta, Vineet Surana, Saptarshi Bhattacharya, Sameer Aggarwal, Meha Sharma   +4 more
doaj   +1 more source